361 related articles for article (PubMed ID: 25896127)
1. Continuation of Statin Therapy and Vasopressor Use in Septic Shock.
Zechmeister C; Hurren J; McNorton K
Ann Pharmacother; 2015 Jul; 49(7):790-5. PubMed ID: 25896127
[TBL] [Abstract][Full Text] [Related]
2. Effects of discontinuing or continuing ongoing statin therapy in severe sepsis and septic shock: a retrospective cohort study.
Mekontso Dessap A; Ouanes I; Rana N; Borghi B; Bazin C; Katsahian S; Hulin A; Brun-Buisson C
Crit Care; 2011 Jul; 15(4):R171. PubMed ID: 21767409
[TBL] [Abstract][Full Text] [Related]
3. A time-sensitive analysis of the prognostic utility of vasopressor dose in septic shock.
Chotalia M; Matthews T; Arunkumar S; Bangash MN; Parekh D; Patel JM
Anaesthesia; 2021 Oct; 76(10):1358-1366. PubMed ID: 33687732
[TBL] [Abstract][Full Text] [Related]
4. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study).
Póvoa PR; Carneiro AH; Ribeiro OS; Pereira AC;
Crit Care Med; 2009 Feb; 37(2):410-6. PubMed ID: 19114885
[TBL] [Abstract][Full Text] [Related]
5. A Non-Comparative Prospective Pilot Study of Ketamine for Sedation in Adult Septic Shock.
Reese JM; Sullivan VF; Boyer NL; Mount CA
Mil Med; 2018 Nov; 183(11-12):e409-e413. PubMed ID: 29800375
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Vasopressor Duration in Septic Shock Patients With and Without Cirrhosis.
Durst MM; Eitzen EA; Benken ST
Ann Pharmacother; 2021 Aug; 55(8):970-979. PubMed ID: 33327736
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock.
Roberts RJ; Miano TA; Hammond DA; Patel GP; Chen JT; Phillips KM; Lopez N; Kashani K; Qadir N; Cairns CB; Mathews K; Park P; Khan A; Gilmore JF; Brown ART; Tsuei B; Handzel M; Chang AL; Duggal A; Lanspa M; Herbert JT; Martinez A; Tonna J; Ammar MA; Nazer LH; Heavner M; Pender E; Chambers L; Kenes MT; Kaufman D; Downey A; Brown B; Chaykosky D; Wolff A; Smith M; Nault K; Gong MN; Sevransky JE; Lat I;
Crit Care Med; 2020 Oct; 48(10):1445-1453. PubMed ID: 32706559
[TBL] [Abstract][Full Text] [Related]
8. Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis.
Bauer SR; Sacha GL; Reddy AJ
Ann Pharmacother; 2020 Apr; 54(4):314-321. PubMed ID: 31679395
[No Abstract] [Full Text] [Related]
9. Effects of Chronic Antihypertensives on Vasopressor Dosing in Septic Shock.
DeMott JM; Patel G; Lat I
Ann Pharmacother; 2018 Jan; 52(1):40-47. PubMed ID: 28799416
[TBL] [Abstract][Full Text] [Related]
10. Effect of norepinephrine on the outcome of septic shock.
Martin C; Viviand X; Leone M; Thirion X
Crit Care Med; 2000 Aug; 28(8):2758-65. PubMed ID: 10966247
[TBL] [Abstract][Full Text] [Related]
11. Effect of statins on the clinical outcomes of patients with sepsis.
Goodin J; Manrique C; Dulohery M; Sampson J; Saettele M; Dabbagh O
Anaesth Intensive Care; 2011 Nov; 39(6):1051-5. PubMed ID: 22165357
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Sepsis and Mortality With Prior Exposure of HMG-COA Reductase Inhibitors in a Surgical Intensive Care Population.
Schurr JW; Wu W; Smith-Hannah A; Smith CJ; Barrera R
Shock; 2016 Jan; 45(1):10-5. PubMed ID: 26674450
[TBL] [Abstract][Full Text] [Related]
13. Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.
Vail E; Gershengorn HB; Hua M; Walkey AJ; Rubenfeld G; Wunsch H
JAMA; 2017 Apr; 317(14):1433-1442. PubMed ID: 28322415
[TBL] [Abstract][Full Text] [Related]
14. Vasopressor weaning in patients with septic shock.
Arellano DL; Hanneman SK
Crit Care Nurs Clin North Am; 2014 Sep; 26(3):413-25. PubMed ID: 25169693
[TBL] [Abstract][Full Text] [Related]
15. The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial.
Cioccari L; Luethi N; Bailey M; Shehabi Y; Howe B; Messmer AS; Proimos HK; Peck L; Young H; Eastwood GM; Merz TM; Takala J; Jakob SM; Bellomo R;
Crit Care; 2020 Jul; 24(1):441. PubMed ID: 32678054
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Vasopressor Discontinuation Strategies in Patients With Septic Shock on Concomitant Norepinephrine and Vasopressin Infusions.
Musallam N; Altshuler D; Merchan C; Zakhary B; Aberle C; Papadopoulos J
Ann Pharmacother; 2018 Aug; 52(8):733-739. PubMed ID: 29560736
[TBL] [Abstract][Full Text] [Related]
17. Impact of Hyperoncotic Albumin on Duration of Vasopressor Support in Septic Shock: A Propensity Score-Matched Analysis.
Flannery AH; Owen GD; Coz A; Thompson Bastin ML; Patel K
Ann Pharmacother; 2021 May; 55(5):584-591. PubMed ID: 33016080
[TBL] [Abstract][Full Text] [Related]
18. Multi-complexity measures of heart rate variability and the effect of vasopressor titration: a prospective cohort study of patients with septic shock.
Brown SM; Sorensen J; Lanspa MJ; Rondina MT; Grissom CK; Shahul S; Mathews VJ
BMC Infect Dis; 2016 Oct; 16(1):551. PubMed ID: 27724850
[TBL] [Abstract][Full Text] [Related]
19. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
[TBL] [Abstract][Full Text] [Related]
20. Practice Patterns and Outcomes Associated With Choice of Initial Vasopressor Therapy for Septic Shock.
Fawzy A; Evans SR; Walkey AJ
Crit Care Med; 2015 Oct; 43(10):2141-6. PubMed ID: 26079345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
